These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 11520837)

  • 41. Strategies for antenatal detection of Down's syndrome.
    Wyllie JP; Madar RJ; Wright M; Burn J; Wren C
    Arch Dis Child Fetal Neonatal Ed; 1997 Jan; 76(1):F26-30. PubMed ID: 9059182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome.
    Kadir RA; Economides DL
    Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down's syndrome.
    Michailidis GD; Spencer K; Economides DL
    BJOG; 2001 Oct; 108(10):1047-52. PubMed ID: 11702836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
    Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
    Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Appraisal of a new scheme for prenatal screening for Down's syndrome.
    Sheldon TA; Simpson J
    BMJ; 1991 May; 302(6785):1133-6. PubMed ID: 1710520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in antenatal screening for Down syndrome.
    Wald NJ; Hackshaw AK
    Baillieres Best Pract Res Clin Obstet Gynaecol; 2000 Aug; 14(4):563-80. PubMed ID: 10985931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost utility of prenatal diagnosis and the risk-based threshold.
    Harris RA; Washington AE; Nease RF; Kuppermann M
    Lancet; 2004 Jan; 363(9405):276-82. PubMed ID: 14751700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-trimester Down's syndrome screening using nuchal translucency: a prospective study in patients undergoing chorionic villus sampling.
    Brambati B; Cislaghi C; Tului L; Alberti E; Amidani M; Colombo U; Zuliani G
    Ultrasound Obstet Gynecol; 1995 Jan; 5(1):9-14. PubMed ID: 7850598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans.
    Howe DT; Gornall R; Wellesley D; Boyle T; Barber J
    BMJ; 2000 Mar; 320(7235):606-10. PubMed ID: 10698877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First trimester, second trimester, and integrated screening for Down's syndrome in China.
    Miao ZY; Liu X; Shi TK; Xu Y; Song QH; Tang SH
    J Med Screen; 2012 Jun; 19(2):68-71. PubMed ID: 22653574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.
    Wald NJ; Hackshaw AK
    Prenat Diagn; 1997 Sep; 17(9):821-9. PubMed ID: 9316126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
    Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
    Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of routine screening for Down's syndrome on the significance of isolated fetal hydronephrosis.
    Thompson MO; Thilaganathan B
    Br J Obstet Gynaecol; 1998 Aug; 105(8):860-4. PubMed ID: 9746378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of the disutility ratio in prenatal screening for Down's syndrome.
    van der Meulen JH; Mol BW; Pajkrt E; van Lith JM; Voorn W
    Br J Obstet Gynaecol; 1999 Feb; 106(2):108-15. PubMed ID: 10426675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Evaluation of Down's syndrome screening methods using maternal serum biochemistry in the second trimester pregnancy].
    Yu DY; Fu P; Zhang ZH; Wang F; Han MY; Ren HY; Zhao W; Zhang K; Li S; Jiang N
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Jun; 28(3):332-5. PubMed ID: 21644235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Introduction of first trimester combined test increases uptake of Down's syndrome screening.
    Tringham GM; Nawaz TS; Holding S; Mcfarlane J; Lindow SW
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):95-8. PubMed ID: 21839574
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin.
    Spencer K; Carpenter P
    BMJ; 1993 Sep; 307(6907):764-9. PubMed ID: 7693095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined first-trimester versus second-trimester serum screening for Down syndrome: a cost analysis.
    Cusick W; Buchanan P; Hallahan TW; Krantz DA; Larsen JW; Macri JN
    Am J Obstet Gynecol; 2003 Mar; 188(3):745-51. PubMed ID: 12634651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of first trimester, second trimester and integrated Down's syndrome screening results in unaffected pregnancies.
    Canini S; Prefumo F; Famularo L; Venturini PL; Palazzese V; De Biasio P
    Clin Chem Lab Med; 2002 Jun; 40(6):600-3. PubMed ID: 12211655
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Second trimester maternal serum screening for Down's syndrome in mainland China: a multi-center prospective study].
    Bian XM; Liu JT; Qi QW; Jiang YL; Li Y; Liu SY; Hao N; Zhou J; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Liao C; Cai Y; Wang H; Wang Z; Zhu J; Hu YL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):805-9. PubMed ID: 19087560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.